Insulet Co. (NASDAQ:PODD) Receives $250.33 Average PT from Analysts

Insulet Co. (NASDAQ:PODD) has earned an average recommendation of “Moderate Buy” from the sixteen analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $250.33.

A number of brokerages have issued reports on PODD. JPMorgan Chase & Co. raised their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Piper Sandler reduced their price objective on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Stifel Nicolaus raised their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Barclays reduced their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research note on Monday, February 26th. Finally, Robert W. Baird raised shares of Insulet from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $180.00 to $238.00 in a research report on Thursday, December 21st.

Insulet Stock Performance

Shares of Insulet stock opened at $173.94 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The firm has a market cap of $12.18 billion, a P/E ratio of 59.77, a P/E/G ratio of 3.15 and a beta of 0.98. The firm has a 50 day simple moving average of $176.32 and a 200 day simple moving average of $178.90. Insulet has a fifty-two week low of $125.82 and a fifty-two week high of $335.91.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same period last year, the firm earned $0.55 earnings per share. The business’s revenue for the quarter was up 37.9% on a year-over-year basis. Sell-side analysts predict that Insulet will post 3.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Shacey Petrovic sold 11,609 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust increased its stake in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares during the last quarter. Allworth Financial LP grew its position in shares of Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 92 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Insulet during the 1st quarter worth approximately $29,000. Wolff Wiese Magana LLC boosted its position in shares of Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 134 shares in the last quarter. Finally, BluePath Capital Management LLC acquired a new stake in shares of Insulet during the 3rd quarter worth approximately $31,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.